By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nabriva Therapeutics 

Leberstrasse 20

Vienna    1112  Austria
Phone: 43-0-1-74093-0 Fax: 43-0-1-74093-1900


Company News
Nabriva Announces Closing Of Its Initial Public Offering 9/24/2015 10:27:49 AM
Should You Invest in Nabriva IPO? 9/18/2015 8:03:28 AM
Nabriva, REGENXBIO, and Penumbra Set to Go Public This Week 9/14/2015 9:27:08 AM
Nabriva Appoints Elyse Seltzer MD As Chief Medical Officer 5/21/2015 9:15:34 AM
Nabriva Presents Data On Extended Spectrum Pleuromutilin Antibiotics At The 25th European Congress Of Clinical Microbiology And Infectious Diseases, Copenhagen 4/24/2015 1:25:06 PM
Nabriva Raises $120 Million, Headed to Phase III for New Antibiotic 4/7/2015 5:50:04 AM
Nabriva Therapeutics Strengthens Board And Management Team 1/29/2015 10:51:08 AM
Nabriva Therapeutics Announces Qualified Infectious Disease Product And Fast Track Status Granted By The US FDA For Lefamulin 10/8/2014 9:16:26 AM
Nabriva Therapeutics Presented Data On Lead Pleuromutilin Antibiotic Lefamulin (BC-3781) At The 54th Interscience Conference On Antimicrobial Agents And Chemotherapy In Washington DC 9/8/2014 9:23:23 AM
Nabriva Therapeutics Appoints Dr. Colin Broom As CEO 9/3/2014 6:37:02 AM